Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: A validation study on us oncology 02-103 clinical trial

BMC Medical Genomics

Volumn 5, Issue , 2012, Pages

  Shen, Kui ^a   Qi, Yuan ^b   Song, Nan ^a   Tian, Chunqiao ^a   Rice, Shara D ^a   Gabrin, Michael J ^a   Brower, Stacey L ^a   Symmans, William Fraser ^c   O'Shaughnessy, Joyce A ^d   Holmes, Frankie A ^e   Asmar, Lina ^f   Pusztai, Lajos ^c  

^a Precision Therapeutics Inc   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e TEXAS ONCOLOGY   (United States)

^f US Oncology Research   (United States)

Author keywords

Breast cancer; Cell lines; Multi gene predictor of chemosensitivity

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DEMOGRAPHY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; UNITED STATES;

EID: 84869074542     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-5-51     Document Type: Article

References (22)

1. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, et al. BMC Genomics 2006 7 127 10.1186/1471-2164-7-127 16729877 (Pubitemid 44027496)
2. Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, et al. J Natl Cancer Inst 2011 103 264 272 10.1093/jnci/djq524 21191116
3. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, et al. Lancet 2003 362 362 369 10.1016/S0140- 6736(03)14023-8 12907009 (Pubitemid 36957839)
4. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, et al. J Clin Oncol 2006 24 4236 4244 10.1200/JCO.2006.05.6861 16896004 (Pubitemid 46630780)
5. Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, et al. Clin Cancer Res 2010 16 5351 5361 10.1158/1078-0432.CCR-10-1265 20829329
6. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, et al. Proc Natl Acad Sci 2007 104 13086 13091 10.1073/pnas. 0610292104 17666531 (Pubitemid 351737597)
7. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology. Baggerly KA, Coombes KR, Ann Appl Stat 2009 3 1309 1334
8. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Sharma SV, Haber DA, Settleman J, Nat Rev Cancer 2010 10 241 253 10.1038/nrc2820 20300105
9. Genomic and molecular profiling predicts response to temozolomide in melanoma. Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, et al. Clin Cancer Res 2009 15 502 510 10.1158/1078-0432.CCR-08-1916 19147755
10. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Liedtke C, Wang J, Tordai A, Symmans W, Hortobagyi G, et al. Breast Cancer Res Treat 2010 121 301 309 10.1007/s10549-009-0445-7 19603265
11. Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. Dawood S, Broglio K, Kau S-W, Green MC, Giordano SH, et al. J Clin Oncol 2009 27 220 226 10.1200/JCO.2008.17. 9952 19047281
12. Pharmacogenomic analysis of needle biopsies obtained before preoperative docetaxel/capecitabine/FEC (TX/FEC) chemotherapy for breast cancer. Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vukelja S, et al. J Clin Oncol 2006 24 18 10595 2006 ASCO Annual Meeting Proceedings
13. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, et al. Eur J Cancer 1998 34 1274 1281 10.1016/S0959-8049(98)00058-6 9849491 (Pubitemid 28342121)
14. Robotic Liquid Handlers and Semiautomated Cell Quantification Systems Increase Consistency and Reproducibility in High-Throughput, Cell-Based Assay. Heinzman JM, Rice SD, Corkan LA, J Assoc Lab Autom 2010 15 7 14 10.1016/j.jala.2009.08.010
15. In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, et al. Clin Cancer Res 2009 15 4649 4664 10.1158/1078-0432.CCR-09-0317 19567590
16. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bolstad BM, Irizarry RA, Åstrand M, Speed TP, Bioinformatics 2003 19 185 193 10.1093/bioinformatics/19.2.185 12538238 (Pubitemid 36181903)
17. Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data. Bair E, Tibshirani R, PLoS Biol 2004 2 108 10.1371/journal.pbio.0020108 15094809 (Pubitemid 39234509)
18. Prediction by Supervised Principal Components. Bair E, Hastie T, Paul D, Tibshirani R, J Am Stat Assoc 2006 101 119 137 10.1198/016214505000000628 (Pubitemid 43500030)
19. HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer. Paik S, Kim C, Wolmark N, N Engl J Med 2008 358 1409 1411 10.1056/NEJMc0801440 18367751 (Pubitemid 351468442)
20. Gene expression profiling predicts clinical outcome of breast cancer. Veer LJ V't, Dai H, Van de Vijver MJ, He YD, Hart AAM, et al. Nature 2002 415 530 536 10.1038/415530a 11823860 (Pubitemid 34130608)
21. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, et al. Clin Cancer Res 2010 16 5222 5232 10.1158/1078-0432.CCR-10-1282 20837693
22. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, et al: Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 2010, 12:R5.